title: HIV/AIDS: modified stem cells in the spotlight.
abstract: Since HIV/AIDS was first recognized in 1981, an urgent need has existed for the development of novel therapeutic strategies to treat the disease. Due to the current antiretroviral therapy not being curative, human stem cell-based therapeutic intervention has emerged as an approach for its treatment. Genetically modified hematopoietic stem cells (HSCs) possess the potential to self-renew, reconstitute the immune system with HIV-resistant cells, and thus control, or even eliminate, viral replication. However, HSCs may be difficult to isolate in sufficient number from HIV-infected individuals for transplantation and/or re-infusion of autologous HSCs preparations would also include some contaminating HIV-infected cells. Furthermore, since genetic modification of HSCs is not completely efficient, the risk of providing unprotected immune cells to become new targets for HIV to infect could contribute to continued immune system failure. Therefore, induced pluripotent stem cells (iPSCs) should be considered a new potential source of cells to be engineered for HIV resistance and subsequently differentiated into clonal anti-HIV HSCs or hematopoietic progeny for transplant. In this article, we provide an overview of the current possible cellular therapies for treating HIV/AIDS.
authors: Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, University of Texas Houston Medical School, Houston, 77030, TX, USA, Enrique.Antonio.ArmijoFuentes@uth.tmc.edu.
authors: Enrique
authors: E
authors: Armijo
authors: Claudio
authors: C
authors: Soto
authors: Brian R
authors: BR
authors: Davis
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy*; D065100:CCR5 Receptor Antagonists; D015658:HIV Infections / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000637:transplantation*; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors
chemical_list: D065100:CCR5 Receptor Antagonists; C527276:CXCR4 protein, human; D019718:Receptors, CXCR4